HeyJaredChristopher Rowland
- Indexed articles, last 90 days
- 3
- Latest publication
- Sep 9, 2026
- Outlet visibility, for The Philadelphia Inquirer, LLC
- Top 50K sites
- Earliest in this view
- Jul 26, 2026
Latest articles
The largely hidden force helping drive Americaâs craze for weight-loss drugs (opens the original)
Read excerpt
Carlos Campos spends most of his days as a family physician, seeing patients for all manner of conditions, especially obesity and diabetes. But he has built a steady side gig beyond his practice in south-central Texas. Over the past seven years, drug manufacturers have paid Campos nearly $1 million to spread the gospel of weight-loss and diabetes drugs known as GLP-1s to colleagues in his home state and beyond. âIâm a lot like an evangelical preacher man,â Campos said. âThey hire me to s
The Trump administration is halting a Medicare drug subsidy. Will premiums rise? (opens the original)
Read excerpt
Medicare drug coverage premiums are expected to rise in 2027 after the Trump administration said Tuesday it would end a temporary subsidy that reduced monthly premiums by an average of $16. But itâs not yet clear how much theyâll increase, or whether they will increase for all Medicare beneficiaries. The loss of the subsidy does not translate directly to how much premiums will rise, because companies that sell Medicare Part D drug coverage take into account many factors when setting rates. T
Some people are getting shut out when it comes to GLP-1 drugs. Hereâs why. (opens the original)
Read excerpt
Primary care doctor Ian Huntington has been counseling low-income Boston patients how to keep their weight under control, after the stateâs Medicaid program stopped covering GLP-1 drugs for weight loss this month. His patients were shedding pounds and getting healthier, exercising more, Huntington said. But now, unable to pay anywhere from $150 to $450 a month in cash, they face the prospect of a devastating weight rebound. âIn some ways, offering the medication for a period of time, and the
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For The Philadelphia Inquirer, LLC, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.